CPHI
Price
$0.98
Change
-$0.08 (-7.55%)
Updated
Aug 21 closing price
Capitalization
42.16M
Intraday BUY SELL Signals
CRON
Price
$3.31
Change
+$0.09 (+2.80%)
Updated
Aug 21 closing price
Capitalization
1.22B
80 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CPHI vs CRON

CPHI vs CRON Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CPHI vs. CRON commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CPHI is a Hold and CRON is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (CPHI: $0.98 vs. CRON: $3.31)
Brand notoriety: CPHI and CRON are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CPHI: 5% vs. CRON: 110%
Market capitalization -- CPHI: $42.16M vs. CRON: $1.22B
CPHI [@Pharmaceuticals: Generic] is valued at $42.16M. CRON’s [@Pharmaceuticals: Generic] market capitalization is $1.22B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CPHI’s FA Score shows that 1 FA rating(s) are green whileCRON’s FA Score has 0 green FA rating(s).

  • CPHI’s FA Score: 1 green, 4 red.
  • CRON’s FA Score: 0 green, 5 red.
According to our system of comparison, CRON is a better buy in the long-term than CPHI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CPHI’s TA Score shows that 4 TA indicator(s) are bullish while CRON’s TA Score has 4 bullish TA indicator(s).

  • CPHI’s TA Score: 4 bullish, 6 bearish.
  • CRON’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRON is a better buy in the short-term than CPHI.

Price Growth

CPHI (@Pharmaceuticals: Generic) experienced а -13.27% price change this week, while CRON (@Pharmaceuticals: Generic) price change was +5.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.60%. For the same industry, the average monthly price growth was +6.53%, and the average quarterly price growth was +30.86%.

Reported Earning Dates

CRON is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.60% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRON($1.22B) has a higher market cap than CPHI($42.2M). CRON YTD gains are higher at: 25.856 vs. CPHI (-19.008). CPHI has higher annual earnings (EBITDA): -1.21M vs. CRON (-2.32M). CRON has more cash in the bank: 822M vs. CPHI (168K). CRON has less debt than CPHI: CRON (1.31M) vs CPHI (3.86M). CRON has higher revenues than CPHI: CRON (160M) vs CPHI (3.99M).
CPHICRONCPHI / CRON
Capitalization42.2M1.22B3%
EBITDA-1.21M-2.32M52%
Gain YTD-19.00825.856-74%
P/E RatioN/A17.47-
Revenue3.99M160M2%
Total Cash168K822M0%
Total Debt3.86M1.31M294%
FUNDAMENTALS RATINGS
CPHI vs CRON: Fundamental Ratings
CPHI
CRON
OUTLOOK RATING
1..100
250
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9689
PRICE GROWTH RATING
1..100
6140
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPHI's Valuation (32) in the Pharmaceuticals Generic industry is in the same range as CRON (45) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to CRON’s over the last 12 months.

CPHI's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as CRON (100) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to CRON’s over the last 12 months.

CRON's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as CPHI (96) in the Pharmaceuticals Generic industry. This means that CRON’s stock grew similarly to CPHI’s over the last 12 months.

CRON's Price Growth Rating (40) in the Pharmaceuticals Other industry is in the same range as CPHI (61) in the Pharmaceuticals Generic industry. This means that CRON’s stock grew similarly to CPHI’s over the last 12 months.

CRON's P/E Growth Rating (98) in the Pharmaceuticals Other industry is in the same range as CPHI (100) in the Pharmaceuticals Generic industry. This means that CRON’s stock grew similarly to CPHI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CPHICRON
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
83%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 12 days ago
80%
Bullish Trend 6 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 10 days ago
78%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
CPHI
Daily Signal:
Gain/Loss:
CRON
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LIDRX12.560.15
+1.21%
Lord Abbett International Value R2
OLVCX22.880.16
+0.70%
JPMorgan Large Cap Value C
RWMAX67.690.34
+0.50%
American Funds Washington Mutual R-1
NSGCX21.940.07
+0.32%
Columbia Cornerstone Equity C
TGVOX32.540.10
+0.31%
TCW Relative Value Mid Cap I

CPHI and

Correlation & Price change

A.I.dvisor tells us that CPHI and CRON have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPHI and CRON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPHI
1D Price
Change %
CPHI100%
-7.55%
CRON - CPHI
23%
Poorly correlated
+2.80%
PAHC - CPHI
22%
Poorly correlated
+3.24%
SXTC - CPHI
22%
Poorly correlated
+12.95%
ACB - CPHI
21%
Poorly correlated
+3.41%
TLRY - CPHI
21%
Poorly correlated
+3.64%
More

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
+2.80%
SNDL - CRON
73%
Closely correlated
+3.01%
ACB - CRON
68%
Closely correlated
+3.41%
CGC - CRON
63%
Loosely correlated
N/A
TRLV - CRON
55%
Loosely correlated
+8.29%
OGI - CRON
52%
Loosely correlated
+4.17%
More